Patent application number | Description | Published |
20080295399 | METHOD FOR FUNGAL BED CULTIVATION OF MUSHROOM - Problem: To provide a method for fungal bed cultivation of a mushroom of a large size having an excellent shape and crunchy texture, a mushroom cutting useful for the fungal bed cultivation method, a culture medium for fungal bed cultivation into which the cutting is transplanted, and a culture medium suitable for fungal bed cultivation. | 12-04-2008 |
20090053383 | ANGELICA KEISKEI TEA - According to the present invention, there are provided kneading-free | 02-26-2009 |
20090148926 | HON-SHIMEJI MUSHROOM-FUNGAL BED CULTURE - Problem: To provide a fungal bed culture enabling stable production of a hon-shimeji mushroom in large scale commercial cultivation as well as a method of fungal bed cultivation of a hon-shimeji mushroom using the fungal bed culture. | 06-11-2009 |
20100139157 | FUNGAL BED CULTIVATION METHOD OF HON-SHIMEJI MUSHROOM - A fungal bed cultivation method of a hon-shimeji mushroom, in which the sprouting step and/or fruit body growing step is carried out under an environmental condition of high CO | 06-10-2010 |
20100143979 | POLYPEPTIDES HAVING DNA POLYMERASE ACTIVITY - A polypeptide having a high fidelity DNA polymerase activity and thus being useful as a genetic engineering reagent; a gene encoding this polypeptide; a method of producing the polypeptide; and a method of amplifying a nucleic acid by using the polypeptide. | 06-10-2010 |
20110171717 | METHOD FOR ENHANCING POLYMERASE ACTIVITY - A polymerase activity is effectively enhanced by adding an anionic surfactant, in particular an anionic surfactant having a polyethoxyl group, to a reaction mixture containing a polymerase. | 07-14-2011 |
20110250230 | CELL CAPABLE OF EXPRESSING EXOGENOUS GITR LIGAND - Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject. | 10-13-2011 |
20110318839 | METHOD FOR ENHANCING A FUNCTION OF A T CELL - Disclosed is a method for enhancing the function of a T cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (PD-L1) and/or programmed death-1 ligand 2 (PD-L2) in the T cell. Also disclosed is a function-enhanced T cell which is produced by the function enhancement method. Further disclosed is a therapeutic agent comprising the function-enhanced T cell. The T cell can enhance an immune response to cancer, and is useful in an immunotherapy effective for cancer and the treatment or prevention of infectious diseases and autoimmune diseases. | 12-29-2011 |
20120009162 | T CELL RECEPTOR AND NUCLEIC ACID ENCODING THE RECEPTOR - Disclosed are: polypeptides for TCR α-chain and β-chain which are restricted to HLA-A*0201 for Aur-A and are derived from a CTL; and nucleic acids encoding the polypeptides. The nucleic acids can impart a cytotoxic activity against a cell capable of presenting an HLA-A*0201 molecule and an Aur-A | 01-12-2012 |
20120083590 | POLYPEPTIDES HAVING DNA POLYMERASE ACTIVITY - A polypeptide having a high fidelity DNA polymerase activity and thus being useful as a genetic engineering reagent; a gene encoding this polypeptide; a method of producing the polypeptide; and a method of amplifying a nucleic acid by using the polypeptide. | 04-05-2012 |
20140120124 | CELL CAPABLE OF EXPRESSING EXOGENOUS GITR LIGAND - Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject. | 05-01-2014 |
20140170709 | VECTOR FOR GENE THERAPY - The present invention provides a retroviral vector containing a transcription unit comprising a transcription regulatory sequence and a gene encoding a polypeptide having single-stranded RNA-specific endoribonuclease activity which is placed so that its expression can be controlled by the regulatory sequence, wherein the unit is placed so that the direction of the transcription of mRNA from the unit is opposite to the direction of transcription of the RNA genome of the retroviral vector. By using the vector constructed as described above, viral supernatant showing high gene transfer efficiency can be prepared. The retroviral vector of the present invention is useful for the treatment and/or prevention of cancers and virus infections. | 06-19-2014 |
20150037300 | NUCLEIC ACID FOR TREATMENT OR PREVENTION OF IMMUNODEFICIENCY VIRUS INFECTION - A nucleic acid comprising a transcription regulation sequence whose transcription is induced by a trans-acting factor of a human immunodeficiency virus and a gene encoding a polypeptide having an endoribonuclease activity specific to single-stranded RNA, wherein the gene is located in such a position that the expression of the gene can be regulated by the transcription regulation sequence; a method for production of a cell showing an inhibited replication of a human immunodeficiency virus therein, the method comprising the step of introducing the nucleic acid into a cell; and a method for treatment or prevention of a human immunodeficiency virus infection. | 02-05-2015 |